



Jing-Zhou Hou, MD PhD

University of Pittsburgh Cancer Centers

Jing-Zhou Hou obtained a degree of Bachelor of Medicine from Zhengzhou University (Henan Medical University), a degree of Master of Medical Science from Fudan University (previously Shanghai Medical University), and a degree of PhD in Molecular and Cellular Biology from Tulane University. Subsequently, he studied apoptosis and its relationship with resistance to chemotherapy in lymphoma cells at National Cancer Institute (NCI, NIH). Dr. Hou completed clinical training in Internal Medicine residency at Northeastern Ohio Universities College of Medicine.

Having had strong interest in hematology and hematological malignancies, Dr. Hou chose and completed his clinical fellowship in Hematology and Medical Oncology at Stanford University. He then continued his clinical and translational research in the division of Blood and Marrow Transplantation at Stanford University School of Medicine. Specifically, he characterized the human T regulatory (Treg) cells from the allogeneic hematopoietic stem cell donors, developed a strategy to purify human Treg in high purity and quantity from these donors for clinical prevention and treatment of acute graft versus host diseases (GVHD). Dr. Hou also has strong research interest in lymphomas and immunotherapy.

Dr. Hou joined Hillman Cancer Center, the flagship cancer center of University of Pittsburgh Medical Center (UPMC) Cancer Centers (the second largest cancer center network in the US) in 2007. Dr. Hou is a clinician and clinical investigator in hematology and BMT. He attends inpatient and outpatient Leukemia/Hematology service and BMT services. He collaborates with laboratory scientist/investigators at University of Pittsburgh Cancer Institute on translational research in immune and cellular therapy in hematological malignancies and BMT. Dr. Hou is board certified in Internal Medicine and Hematology.

Dr. Hou serves as the chair of the lymphoma pathway committee at UPMC Cancer Centers. The committee is responsible to develop a single best modality/regimen for different types of Hodgkin's Lymphoma and Non-Hodgkin's Lymphomas basing on the best available clinical evidences after vigorous internal review and debate. Dr. Hou also serves in the Protocol Scientific Review Committee for UPMC Cancer Centers, and actively participates in the various clinical educational activities for fellows, residents, and medical students. Dr. Hou has been a member of CAHON since her birth.